Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy.
Wiendl H, Schmierer K, Hodgkinson S, Derfuss T, Chan A, Sellebjerg F, Achiron A, Montalban X, Prat A, De Stefano N, Barkhof F, Leocani L, Vermersch P, Chudecka A, Mwape C, Holmberg KH, Boschert U, Roy S; MAGNIFY-MS Study Group. Wiendl H, et al. Among authors: boschert u. Neurol Neuroimmunol Neuroinflamm. 2022 Nov 21;10(1):e200048. doi: 10.1212/NXI.0000000000200048. Print 2023 Jan. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36411081 Free PMC article.
Molecular signature associated with cladribine treatment in patients with multiple sclerosis.
Fissolo N, Calvo-Barreiro L, Eixarch H, Boschert U, Villar LM, Costa-Frossard L, Ferrer M, Sanchez A, Borràs E, Sabidó E, Espejo C, Montalban X, Comabella M. Fissolo N, et al. Among authors: boschert u. Front Immunol. 2023 Jul 25;14:1233546. doi: 10.3389/fimmu.2023.1233546. eCollection 2023. Front Immunol. 2023. PMID: 37559720 Free PMC article.
Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib.
Rijvers L, van Langelaar J, Bogers L, Melief MJ, Koetzier SC, Blok KM, Wierenga-Wolf AF, de Vries HE, Rip J, Corneth OB, Hendriks RW, Grenningloh R, Boschert U, Smolders J, van Luijn MM. Rijvers L, et al. Among authors: boschert u. JCI Insight. 2022 Aug 22;7(16):e160909. doi: 10.1172/jci.insight.160909. JCI Insight. 2022. PMID: 35852869 Free PMC article.
Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis.
Schmierer K, Wiendl H, Oreja-Guevara C, Centonze D, Chudecka A, Roy S, Boschert U. Schmierer K, et al. Among authors: boschert u. Mult Scler. 2022 Nov;28(13):2151-2153. doi: 10.1177/13524585221099413. Epub 2022 Jun 7. Mult Scler. 2022. PMID: 35672923 Free PMC article. No abstract available.
Immunomodulatory Effects Associated with Cladribine Treatment.
Fissolo N, Calvo-Barreiro L, Eixarch H, Boschert U, Espejo C, Montalban X, Comabella M. Fissolo N, et al. Among authors: boschert u. Cells. 2021 Dec 10;10(12):3488. doi: 10.3390/cells10123488. Cells. 2021. PMID: 34943995 Free PMC article.
Different Susceptibility of T and B Cells to Cladribine Depends On Their Levels of Deoxycytidine Kinase Activity Linked to Activation Status.
Carlini F, Ivaldi F, Gualandi F, Boschert U, Centonze D, Matarese G, Salvetti M, Kerlero de Rosbo N, Uccelli A. Carlini F, et al. Among authors: boschert u. J Neuroimmune Pharmacol. 2022 Jun;17(1-2):195-205. doi: 10.1007/s11481-021-09994-3. Epub 2021 Apr 14. J Neuroimmune Pharmacol. 2022. PMID: 33851318 Free PMC article.
47 results